Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Intellipharmaceutics International Inc V.IPCI.H

Alternate Symbol(s):  IPCIQ

Intellipharmaceutics International Inc. is a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs. Its Hypermatrix technology is a multidimensional controlled-release drug delivery platform that can be applied to a range of existing and new pharmaceuticals. It has developed several drug delivery systems based on this technology platform, with a pipeline of products in various stages of development. The Company has ANDA and NDA 505(b)(2) drug product candidates in its development pipeline. These include the Company’s abuse-deterrent oxycodone hydrochloride extended-release formulation (Oxycodone ER) based on its proprietary nPODDDS novel Point of Divergence Drug Delivery System (for which an NDA has been filed with the FDA), and Regabatin XR (pregabalin extended-release capsules). Its product portfolio includes both new products and controlled-release generic products.


TSXV:IPCI.H - Post by User

Post by Fonzieeon Jan 19, 2020 8:38pm
327 Views
Post# 30571843

Pill deserved the no vote but it's an easy fix.

Pill deserved the no vote but it's an easy fix.
The pill its easier to crush and snort which is the main way of abuse. Also it has a more intense rapid onset when snorted so it is ideal for the ABUSER! That's why it failed. Ipci has nailed down the Iv side. Ipci needs to put that dye back in they took out listening to the fda and if possible make pill abit harder if not the dye takes care of the nasal route and it's a done deal. Why no one from ipci said anything about this at the meeting is beyond me. Getting it fixed quick which they already know how to do and resubmit for approval and lets get this show on the road
<< Previous
Bullboard Posts
Next >>